Aseala I Abousaud1, Meagan S Barbee2, Christine C Davis3, Sarah E Caulfield3, Zeyuan Wang4, Alexa Boykin5, Bradley C Carthon6, Keerthi Gogineni6. 1. Department of Pharmaceutical Services, Emory Healthcare, 5665 Peachtree Dunwoody Road NE, Atlanta, GA 30342, USA. 2. Global Medical Information Specialist, Oncology at Med Communications Inc. 3. Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA. 4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health. 5. Medical Science Liason, Novocure Inc., Atlanta, GA, USA. 6. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Abstract
AIM: More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts and their precursors. The United States Food and Drug Administration (FDA)-approved dose of denosumab is 120 mg every 4 weeks; however, other schedules have been used in practice for patient convenience. Evidence for the safety and efficacy of alternative dosing intervals is lacking. PATIENT & METHODS: Adult patients with solid cancers and bone metastases who received at least two doses of denosumab 120 mg were reviewed. Patients were grouped based on an average denosumab dosing interval of <5 weeks (short-interval) versus 5-11 weeks (medium-interval) versus ⩾12 weeks (long-interval). The primary outcome was the time to first SRE while on denosumab between the short- and medium-interval groups. The secondary outcomes were overall survival (OS), efficacy comparisons between the other groups, and safety events. RESULTS: There was no significant difference in median time to first SRE between the short- and medium-interval denosumab groups [33.2 versus 28.4 months, hazard ratio (HR): 1.13, 95% confidence interval (CI): 0.66-1.92, p = 0.91] or the medium- and long-interval dosing groups (28.4 versus 32.2 months, HR: 1.15, 95% CI: 0.66-2.01, p = 0.62). Median OS was not found to differ significantly between any of the groups. There were significantly more hospitalizations in the short-interval dosing group than the other groups (55.2% versus 33.8% versus 30.4%, p < 0.001). CONCLUSION: Extending denosumab dosing intervals does not appear to negatively impact time to first SRE and is associated with fewer hospitalizations in real-world patients with solid cancers and bone metastases.
AIM: More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts and their precursors. The United States Food and Drug Administration (FDA)-approved dose of denosumab is 120 mg every 4 weeks; however, other schedules have been used in practice for patient convenience. Evidence for the safety and efficacy of alternative dosing intervals is lacking. PATIENT & METHODS: Adult patients with solid cancers and bone metastases who received at least two doses of denosumab 120 mg were reviewed. Patients were grouped based on an average denosumab dosing interval of <5 weeks (short-interval) versus 5-11 weeks (medium-interval) versus ⩾12 weeks (long-interval). The primary outcome was the time to first SRE while on denosumab between the short- and medium-interval groups. The secondary outcomes were overall survival (OS), efficacy comparisons between the other groups, and safety events. RESULTS: There was no significant difference in median time to first SRE between the short- and medium-interval denosumab groups [33.2 versus 28.4 months, hazard ratio (HR): 1.13, 95% confidence interval (CI): 0.66-1.92, p = 0.91] or the medium- and long-interval dosing groups (28.4 versus 32.2 months, HR: 1.15, 95% CI: 0.66-2.01, p = 0.62). Median OS was not found to differ significantly between any of the groups. There were significantly more hospitalizations in the short-interval dosing group than the other groups (55.2% versus 33.8% versus 30.4%, p < 0.001). CONCLUSION: Extending denosumab dosing intervals does not appear to negatively impact time to first SRE and is associated with fewer hospitalizations in real-world patients with solid cancers and bone metastases.
Authors: Ana Boquete-Castro; Gerardo Gómez-Moreno; José Luis Calvo-Guirado; Antonio Aguilar-Salvatierra; Rafael Arcesio Delgado-Ruiz Journal: Clin Oral Implants Res Date: 2015-02-02 Impact factor: 5.977
Authors: David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: M F K Ibrahim; S Mazzarello; R Shorr; L Vandermeer; C Jacobs; J Hilton; B Hutton; M Clemons Journal: Ann Oncol Date: 2015-06-28 Impact factor: 32.976
Authors: Allan Lipton; Guenther G Steger; Jazmin Figueroa; Cristina Alvarado; Philippe Solal-Celigny; Jean-Jacques Body; Richard de Boer; Rossana Berardi; Pere Gascon; Katia S Tonkin; Robert Coleman; Alexander H G Paterson; Mark C Peterson; Michelle Fan; Amy Kinsey; Susie Jun Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Benoit Cadieux; Robert Coleman; Pegah Jafarinasabian; Allan Lipton; Robert Z Orlowski; Fred Saad; Giorgio V Scagliotti; Kazuyuki Shimizu; Alison Stopeck Journal: J Bone Oncol Date: 2022-02-07 Impact factor: 4.072
Authors: Ingo J Diel; Richard Greil; Jan Janssen; Christian W Kluike; Bagmeet Behera; Ali Abbasi; Anouchka Seesaghur; Michael Kellner; Christine Jaeger; Katja Bjorklof; Antoaneta Tomova; Ferdinand Haslbauer Journal: Support Care Cancer Date: 2022-09-06 Impact factor: 3.359